P(A) Event Hall

1 P(A). Event Hall P-2080 P-2293 P-2085 P-2092 P-2306. 98. 20. P-2081 P-2292 P-2086 P-2299 P-2093 P-2305. P- 99. P- 20. 22. P- 00. P-2082 P-2291 P-2087 P-2298 P-2094 P-2304. 86. 21. P- 22. P- 01. 85. 21. P- P-2083 P-2290 P-2088 P-2297 P-2095 P-2303. 22. P- 02. 84. 21. P- 22. P- 83 P-2084 P-2289 P-2089 P-2296 P-2096 P-2302. P- 22. 82. P-2288 P-2090 P-2295 P-2097 P-2301. P- 22. 81. P- P-2287 P-2091 P-2294 P-2300. 22. 80. P-2103. P-2104. P-2047 P-2054 P-2061 P-2066 P-2073 P-2274 P-2105. P-2048 P-2250 P-2055 P-2256 P-2062 P-2262 P-2067 P-2074 P-2273 P-2106. P-2107. P-2108. P-2109. P-2049 P-2249 P-2056 P-2255 P-2063 P-2261 P-2068 P-2267 P-2075 P-2272. P-2050 P-2248 P-2057 P-2254 P-2064 P-2260 P-2069 P-2266 P-2076 P-2271. P-2040. P-2041. P-2042. P-2043. P-2044. P-2045. P-2046. P-2077 P-2270.

2 P-2276. SSP-11 P-2275. P-2051 P-2247 P-2058 P-2253 P-2065 P-2259 P-2070 P-2265. P-2279. P-2278. P-2277. P-2052 P-2246 P-2059 P-2252 P-2258 P-2071 P-2264 P-2078 P-2269. SSP-1. P-2053 P-2245 P-2060 P-2251 P-2257 P-2072 P-2263 P-2079 P-2268 .. P-2001 P-2005 P-2012 P-2219 P-2017 P-2023 P-2232 P-2029 P-2239 P-2035. P-2002 P-2207 P-2006 P-2013 P-2218 P-2018 P-2225 P-2024 P-2231 P-2030 P-2238 P-2036. P-2003 P-2206 P-2007 P-2212 P-2014 P-2217 P-2019 P-2224 P-2025 P-2230 P-2031 P-2237 P-2037 P-2244. P-2004 P-2205 P-2008 P-2211 P-2015 P-2216 P-2020 P-2223 P-2026 P-2229 P-2032 P-2236 P-2038 P-2243. P-2390 P-2204 P-2009 P-2210 P-2016 P-2215 P-2021 P-2222 P-2027 P-2228 P-2033 P-2235 P-2039 P-2242. P-2203 P-2010 P-2209 P-2214 P-2022 P-2221 P-2028 P-2227 P-2034 P-2234 P-2241. P-2202 P-2011 P-2208 P-2388 P-2213 P-2220 P-2226 P-2233 P-2240.

3 16:30-17:15 17:15-18:00. P-2001 ..P1-3 DNA damage response P-2202 ..P1-4 Process of carcinogenesis P-2005 ..P2-2 Animal models for cancer (2) P-2208 ..P3-5 HPV. P-2012 ..P3-4 Inflammation and cancer (2) P-2213 ..P4-7 Oncogenes and tumor-suppressor genes (2). P-2017 ..P4-6 New oncogenes and tumor suppressor genes P-2220 ..P5-5 Transcriptional regulation (1). P-2023 ..P5-4 Signal transduction of cancer cells and inhibitors (2) P-2226 ..P5-6 MicroRNAs (2). P-2029 ..P7-3 Cancer genomic analysis (2) P-2233 ..P8-2 Various modes of cell death P-2035 ..P9-3 Involvement of aberrant DNA methylation in cancer P-2240 ..P9-4 Histone modification (2). P-2040 ..P10-6 Molecular pathology of cancer behavior (3) P-2245 ..P10-8 Metastasis related genes and angiogenesis P-2047 ..P10-7 Molecular mechanisms of invasion and metastasis P-2251.

4 P10-9 Substances suppressing invasion and metastasis P-2054 ..P11-8 Cancer stem cell (4) P-2257 ..P11-10 Metabolic reprogramming in cancer P-2061 ..P11-9 Metabolism in cancer (2) P-2263 ..P12-7 Innate immunity (1). P-2066 ..P12-4 Antitumor effector cells and their induction (1) P-2268 ..P12-8 Vaccination therapy P-2073 ..P12-5 New antibody-based therapy P-2275 ..P12-9 Development of vaccination therapy P-2080 ..P12-6 Current status and issues in immune checkpoint blockade therapy P-2280 ..P13-3 Tumor microenvironment P-2085 ..P13-2 Growth factor and cytokine (2) P-2287 ..P14-40 Gastric cancer: prognosis/biomarker P-2092 ..P14-28 Gastric cancer: invasion and metastasis P-2294 ..P14-36 Biliary tract cancer (1). P-2098 ..P14-35 Tumor microenvironment and novel treatments in esophageal cancer P-2300.

5 P14-37 Pancreatic cancer (4). P-2103 ..P14-24 Colorectal cancer: basic (1) SSP-1 ..SSP Survivor Scientist Program 158. Room P. P(B). INFORMATION. New Hall DAY 1. P-2190. P-2191. P-2192. P-2193. P-2194. P-2195. P-2196. P-2197. P-2198. P-2199. P-2200. P-2201. AM. P-2185 P-2373. P-2186 P-2372. P-2187 P-2371. P-2188 P-2370. P-2189 P-2369. P-2145 P-2341. P-2146 P-2340. P-2147 P-2339. P-2148 P-2338. P-2337. P-2336. LS. P-2144. P-2183. P-2184. PM. Posters P-2176 P-2368. P-2177 P-2367. P-2178 P-2366. P-2179 P-2365. P-2180 P-2364. P-2181 P-2363. P-2139 P-2335. P-2140 P-2334. P-2141 P-2333. P-2142 P-2332. P-2143 P-2331. P-2175 P-2182. P-2387. P-2386. P-2137. P-2138. P-2385. DAY 2. P-2384. P-2168 P-2362. P-2169 P-2361. P-2170 P-2360. P-2171 P-2359. P-2172 P-2358. P-2173 P-2357. P-2174 P-2356. P-2330.

6 P-2132 P-2329. P-2133 P-2328. P-2134 P-2327. P-2135 P-2326. P-2136 P-2325. P-2383. AM. P-2382. P-2130. P-2131. LS. P-2381. P-2165 P-2355. P-2166 P-2354. P-2353. P-2352. P-2126 P-2324. P-2127 P-2323. P-2129 P-2321. P-2320. P-2162 P-2167. P-2322. PM. P-2380. Posters P-2124. P-2125. P-2128. P-2164. P-2163. P-2379. P-2117 P-2319. P-2118 P-2318. P-2119 P-2317. P-2120 P-2316. P-2121 P-2315. P-2122 P-2314. P-2123 P-2313. P-2155 P-2389. P-2156 P-2351. P-2157 P-2350. P-2158 P-2349. P-2159 P-2348. P-2160 P-2347. P-2161 P-2346. P-2378. DAY 3. P-2377. P-2376. P- AM. P-2375. P-2115 P-2308. P-2116 P-2307. P-2111 P-2312. P-2112 P-2311. P-2113 P-2310. P-2114 P-2309. P-2152 P-2345. P-2153 P-2344. P-2154 P-2343. P-2342. P-2374. LS. P-2110. P-2149. P-2151. P-2150. 16:30-17:15 17:15-18:00 PM. Posters INDEX.

7 P-2110 ..P14-25 Hepatocellular carcinoma (2) P-2307 ..P14-38 Predictive and prognostic marker in lung cancer (2). P-2117 ..P14-26 Pancreatic cancer (3) P-2313 ..P14-39 Breast cancer (4) issues and new approaches P-2124 ..P14-27 Molecular pathogenesis and treatment of P-2320 ..P14-41 Hematological malignancies (2). lung cancer (2) P-2325 ..P14-42 Renal cell carcinoma (3) / bladder cancer (1). P-2130 ..P14-30 Breast cancer (3) current topics P-2331 ..P14-43 Bone and soft tissue tumor - genome analyses and new treatment Authors P-2137 ..P14-31 Renal cell carcinoma (2) P-2336 ..P14-44 Head and neck cancer, chemotherapy / prognostic factor P-2144 ..P14-32 Prostate cancer (2) P-2342 ..P14-45 Skin cancer P-2149 ..P14-33 Head and neck cancer, pathology / imaging P-2346 ..P15-7 Development of novel biomarker of cancer (2).

8 P-2155 ..P14-34 Head and neck cancer, P-2352 ..P15-8 Novel diagnostic tools (3). Keywords Chairpersons oncogenes andtumor-suppressor genes P-2356 ..P16-2 Signal transduction inhibitors / kinase inhibitors (1). P-2162 ..P15-6 Novel diagnostic tools (2) P-2363 ..P16-3 Oncogenic pathway and molecular targets for cancer therapy P-2167 ..P16-1 Peptides and antibodies in cancer therapy P-2369 ..P18-1 Pharmacokinetics / pharmacogenomics P-2175 ..P17-3 Natural anticancer compounds (2) P-2374 ..P21 Gene therapy and oncolytic virus therapy P-2182 ..P19 Radiation, particle therapy, others P-2379 ..P24-2 Descriptive epidemiology and model of cancer occurrence P-2190 ..P22-1 Cancer treatment and their mechanisms P-2382 ..P25-1 Cancer bioinformatics (1). P-2196 ..P24-1 Gene-environmental interaction and individual cancer risk 159.

9 1 Chemical carcinogenesis and radiation carcinogenesis P-2006 Downregulation of Inpp5f protein in MEK-inhibitor resistant intestinal adenocarcinomas of cis-Apc/Smad4 mice Room P(A) Sep. 27 (Fri.) 16:30-17:15 E/J Teruaki Fujishita1, Emi Mishiro1, Yasushi Kojima1, Makoto M. Taketo3, DNA damage response Masahiro Aoki1,2 (1 Div. Pathophysiol., Aichi Cancer Ctr. Res. Inst., 2 Div. P1-3 Cancer Physiol., Nagoya Univ. Grad. Sch. Med., 3 Div. Exp. Therap., DNA . Kyoto Univ. Grad. Sch. Med.). Chairperson: Tsuyoshi Ikura (Lab. of Chromatin Regulatory Network, Dept. cis-Apc/Smad4 MEK . Genome Biol., Radiation Biol. Ctr., Grad. Sch. of Biostudies, Kyoto Inpp5f . Univ.) 1 1 1 3 1,2 1 . 2 3 .. P-2001 REV7 expression is associated with disease progression of malignant P-2007 Establishment and functional analysis of Pten haploinsufficient melanoma colon cancer organoid models derived from mouse models Akiyoshi Hoshino, Masaaki Ichinoe, Yasutaka Sakurai, Yoshiki Haruki Sada1,2, Takao Hinoi3, Naoya Sakamoto4, Kazuhiro Sentani4, Murakumo (Dept.)

10 Patho., Kitasato Univ., Sch. Med.) Naohide Oue4, Wataru Yasui4, Hirotaka Tashiro2, Hideki Ohdan1. REV7 (1 Dept. Gastroenterol Transplant Surg., Hiroshima Univ., 2 Dept. Surg., Kure Med. Ctr., 3 Dept. Clin. & Mol. Genetics, Hiroshima Univ., 4 Dept. Mol. Path., Hiroshima Univ.). P-2002 Development and Application of A Novel Fluorescent probe for Pten . Detection of Intracellular Cholesterol . Yuki Tatenaka (Dojindo Lab., R&D Dept.) 1,2 3 4 4 4 . 4 2 1 1 2 .. 3 4 .. P-2003 Prevention of 11q23 chromosomal translocations by ATM and ATR P-2008 Functional analysis of the HIF activation factor Mint3 in tumor- through the phosphorylation of ARP8 associated macrophages Jiying Sun, Satoshi Tashiro (Dept. Cell. Biol., RIRBM, Hiroshima Yuya Fukui1, Yoshinori Murakami2, Jun-ichiro Inoue1, Takeharu Univ.